Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.47 |
| ▸ | TYMS | P04818 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60737 | 0.90 | TK1 (0.52) | TK1TYMS | |
| SCHEMBL9564565 | 0.90 | TK1 (0.52) | TK1TYMS | |
| SCHEMBL7535867 | 0.90 | TK1 (0.52) | TK1TYMS | |
| SCHEMBL5486404 | 0.90 | LMNA (0.47) | TK1TYMS | |
| SCHEMBL1501551 | 0.90 | TYMS (0.44) | TK1TYMS | |
| SCHEMBL5086839 | 0.88 | TK1 (0.46) | TK1TYMSBCHE | |
| SCHEMBL2027058 | 0.88 | LMNA (0.50) | TK1TYMS | |
| SCHEMBL8892073 | 0.88 | TYMS (0.43) | TK1TYMS | |
| SCHEMBL2030341 | 0.87 | TYMS (0.44) | TK1TYMS | |
| SCHEMBL7602619 | 0.87 | TK1 (0.43) | TK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067824-A1 | SULFORHODAMINE PHOSPHORAMIDITE DYES | CEPHEID | 2024-02-29 | — | — | US | disclosed |
| EP-3790931-B1 | SULFORHODAMINE PHOSPHORAMIDITE DYES | CEPHEID (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3790931-A1 | SULFORHODAMINE PHOSPHORAMIDITE DYES | Cepheid (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217470-A1 | SULFORHODAMINE PHOSPHORAMIDITE DYES | CEPHEID (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20080032413-A1 | Oligonucleotide For Detecting Target Dna Or Rna | POSTECH FOUNDATION (KR) | 2008-02-07 | — | — | US | disclosed |
| US-7019135-B2 | Anti-viral pyrimidine nucleoside analogues | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-03-28 | — | — | US | disclosed |
| WO-2005098036-A1 | OLIGONUCLEOTIDE FOR DETECTING TARGET DNA OR RNA | POSTECH FOUNDATION (KR) | 2005-10-20 | — | — | WO | disclosed |
| EP-1280813-B1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIV CARDIFF (GB) | 2003-11-12 | — | — | EP | disclosed |
| US-20030176370-A1 | Anti-viral pyrimidine nucleoside analogues | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-6573247-B1 | Prophylaxis or treatment of varicella-zoster virus or cytomegalo virus infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2003-06-03 | — | — | US | disclosed |
| EP-0980377-B1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIV CARDIFF (GB) | 2002-07-31 | — | — | EP | disclosed |
| US-5633361-A | OLIGONUCLEOTIDES | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5591843-A | 5-modified pyrimidines from palladium catalyzed carbon-carbon coupling | EATON BRUCE (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0702675-A1 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702675-A4 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | UNIV WASHINGTON (US) | 1996-02-02 | — | — | EP | disclosed |
| US-5428149-A | Reacting vinyl and aryl stannanes with 2'-deoxy-5-halo-uridine | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1994029279-A1 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176370-A1 | Anti-viral pyrimidine nucleoside analogues | CCNO, TYMP, TK1 | TK1 3/4885TYMS 12/4885BCHE 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.